Dyfyniad APA

Do, K., Speranza, G., Bishop, R., Khin, S., Rubinstein, L., Kinders, R. J., . . . Kummar, S. (2015). Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest New Drugs.

Dyfyniad Arddull Chicago

Do, Khanh, et al. "Biomarker-driven Phase 2 Study of MK-2206 and Selumetinib (AZD6244, ARRY-142886) in Patients With Colorectal Cancer." Invest New Drugs 2015.

Dyfyniad MLA

Do, Khanh, et al. "Biomarker-driven Phase 2 Study of MK-2206 and Selumetinib (AZD6244, ARRY-142886) in Patients With Colorectal Cancer." Invest New Drugs 2015.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.